inavolisib (Selleck Chemicals)
Selleck Chemicals is a verified supplier 
Selleck Chemicals manufactures this product 
93
Structured Review
Selleck Chemicals
inavolisib
Inavolisib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdc+0077/GDC-0077/pmc12820070-243-0-1
Average 93 stars, based on 7 article reviews
Inavolisib, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gdc+0077/GDC-0077/pmc12820070-243-0-1
Average 93 stars, based on 7 article reviews
inavolisib - by Bioz Stars,
2026-10
93/100 stars
Images
Related Articles
Transduction:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: Recombinant:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: Saline:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: Software:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: Sterility:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: Transferring:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: Ointment:Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: TBK1 inhibitor GSK8612 was used at 16 μM ( Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM (S7128, Selleckchem), ipatasertib was used at 5 μM (S2808, Selleckchem), BYL719 was used at 5 μM (S2814, Selleckchem), GDC0077 was used at 5 μM (S8668, Selleckchem), GDC0941 was used at 3 μM (S1065, Selleckchem), MAK683 was used at 5 μM (S8983, Article Title: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Article Snippet: For all assays except synergy assays, tazemetosat was used at 5 μM ( Article Title: A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities Article Snippet: |
